The Filing Desk

EyePoint vs Foghorn Therapeutics

EyePoint EYPT · Foghorn Therapeutics FHTX · Pharmaceuticals

EyePoint reported revenue of $31 million in fiscal 2025, about the same as Foghorn Therapeutics' $31 million in fiscal 2025. EyePoint's revenue fell 27.5% in its latest year, and Foghorn Therapeutics' grew 36.8%. EyePoint had an operating margin of -776.0%, against -279.5% at Foghorn Therapeutics. Free cash flow was −$243 million at EyePoint and −$86 million at Foghorn Therapeutics.

Side by side

EyePointFoghorn Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$31M$31M
Revenue growth−27.5%36.8%
Revenue growth a year, last 5 years−1.8%138.6%
Gross margin——
Operating margin−776.0%−279.5%
Net margin−739.4%−240.3%
Free cash flow−$243M−$86M
Free cash flow margin−775.8%−278.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count30.1%14.7%
Last close$0.26$1.78
P/E at the last close—25.4×
Insider trades, last 12 monthsbought $71,983, sold $0—
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
EyePointFoghorn Therapeutics
Operating margin
Percent of revenue
EyePointFoghorn Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EyePointFoghorn Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the EyePoint and Foghorn Therapeutics pages.